Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates
How to Cite
OrthoEvidence. Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates. ACE Report. 2017;6(1):48. Available from: https://myorthoevidene.com/AceReport/Report/9245
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesJ Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
643 postmenopausal women with osteoporosis who had used oral bisphosphonate for a minimum of 2 years were randomized to either subcutaneous injections of denosumab 60mg - one at baseline and another at 6 months - or intravenous injection of zoledronic acid 5mg. The purpose of this study was to evaluate if denosumab offered noninferior or superior efficacy and safety to zoledronic acid for increasi...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE